Scadenza: 27 October 2021
Topic:
The aim of this EIC Pathfinder Challenge, is to fund proposals focused on novel conceptbased technologies that can contribute to the development of more effective cell and gene therapy (CGT) treatments, and on technological solutions beyond the state-of-the-art, that have the potential to overcome critical challenges currently being faced by the cell and gene therapy research community and innovation-based industry.
The Challenge as described in the Work Programme has the following objectives:
advancing cell therapy manufacturing and products to a clinical stage,
improving adoptive cell therapies (CAR-T, TCR, TIL),
identifying next-generation cell therapies for cancer,
applying cell therapy to treat cancer patients in a personalised manner,
improving the effectiveness and lowering the risks of gene delivery systems (vectors), and
improving gene therapy manufacturing processes and production.
In addition, with this Call, EIC aims at bringing together leading consortia and promising start-ups targeted to the above-mentioned areas creating a critical mass in these areas, which, in turn, can enhance the European technological sovereignty in the cell and gene therapy field.
Programma:
Horizon Europe – the Framework Programme for Research and Innovation
Ente finanziatore:
EU
Budget complessivo:
132.000.000
Who can participate:
This Pathfinder Challenge supports collaborative research and innovation from consortia or applications from single legal entities. In case of a consortium your proposal must be submitted by the coordinator on behalf of the consortium that includes at least two independent legal entities. Consortia of two must have independent legal entities from two different Member States or Associated Countries. Consortia of three or above follow standard rules i.e. at least one legal entity must be from a Member State.The legal entities may for example be universities, research organisations, SMEs, start-ups, natural persons. In the case of monobeneficiary projects, mid-caps and larger companies will not be permitted.
Status:
Closed
Quota finanziabile:
100%
Topic:
The aim of this EIC Pathfinder Challenge, is to fund proposals focused on novel conceptbased technologies that can contribute to the development of more effective cell and gene therapy (CGT) treatments, and on technological solutions beyond the state-of-the-art, that have the potential to overcome critical challenges currently being faced by the cell and gene therapy research community and innovation-based industry.
The Challenge as described in the Work Programme has the following objectives:
advancing cell therapy manufacturing and products to a clinical stage,
improving adoptive cell therapies (CAR-T, TCR, TIL),
identifying next-generation cell therapies for cancer,
applying cell therapy to treat cancer patients in a personalised manner,
improving the effectiveness and lowering the risks of gene delivery systems (vectors), and
improving gene therapy manufacturing processes and production.
In addition, with this Call, EIC aims at bringing together leading consortia and promising start-ups targeted to the above-mentioned areas creating a critical mass in these areas, which, in turn, can enhance the European technological sovereignty in the cell and gene therapy field.
Who can participate:
This Pathfinder Challenge supports collaborative research and innovation from consortia or applications from single legal entities. In case of a consortium your proposal must be submitted by the coordinator on behalf of the consortium that includes at least two independent legal entities. Consortia of two must have independent legal entities from two different Member States or Associated Countries. Consortia of three or above follow standard rules i.e. at least one legal entity must be from a Member State.The legal entities may for example be universities, research organisations, SMEs, start-ups, natural persons. In the case of monobeneficiary projects, mid-caps and larger companies will not be permitted.
Programme:
Horizon Europe – the Framework Programme for Research and Innovation
Consortium:
Status: Open
Total budget:
132.000.000
Funding rate:
100%
